Description: The first clinical candidate in the novel antibiotic class Odilhorhabdins.

Mode of Action (MoA): Inhibition of bacterial ribosome via a new mechanism.

Description: Boosts ethionamide efficacy and lowers the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections.

Mode of Action (MoA): Bacterial transcriptional regulation.

Description: Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

Mode of Action (MoA): Topoisomerase type II inhibitor.

Description: Molecule targeting mycobacterial cholesterol cycle.

Mode of Action (MoA): Cholesterol catabolism.

Description: Compound targets tryptophan biosynthesis pathway.

Mode of Action (MoA): Mycobacterium tuberculosis tryptophan synthase, the enzyme that catalyses the final two steps in tryptophan biosynthesis. pathway

Description: Compounds targeting energy metabolism.

Mode of Action (MoA): Electron chain transport.

Description: Compound targets an essential gene.

Mode of Action: Lysine transfer RNA synthase (essential gene as assessed by transposon mutagenesis).

Description: Potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis.

Mode of Action: Mycobacterial membrane protein Large 3 (Mmpl3)

Description: Natural product analogs active against Mycobacterium tuberculosis.

Mode of Action (MoA): Unknown.

Description: Derivative of piperazinobenzothiazinone that acts as an anti-mycobacterial compound.

Mode of Action (MoA): Targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).

Description: Lead optimisation program on BC1 inhibitors.

Mode of Action (MoA): Cytochrome bc1 complex in the cellular respiration pathway.

Description: Target exploration of an essential complex modulating resistance.

Mode of Action (MoA): Mycothione reductase (Mtr).

Description: Novel assets (one first-in-human start) that may synergise with bedaquiline and cytochrome bc1 drugs.

Mode of Action (MoA): Not unkown.

Description: A first-in-class investigational antitubercular agent is being developed to treat tuberculosis as part of a future combination regimen.

Mode of Action (MoA):  Suppresses protein synthesis in Mycobacterium tuberculosis by inhibiting the enzyme leucyl t-RNA synthetase (LeuRS).

Description: A first-in-class investigational antitubercular agent is being developed to treat tuberculosis as part of a future combination regimen.

Mode of Action (MoA): Inhibits an essential enzyme for cell wall synthesis in Mycobacteria tuberculosis.

Description: Small molecule oxaborole.

Mode of Action (MoA): Inhibits leucyl tRNA synthetase (LeuRS)

Description: Targets cholesterol cycle in Mycobacterium tuberculosis.

Mode of Action (MoA): Cholesterol catabolism.

Description: Small molecule compound that leads to the depletion of ATP in three mycobacterial species, M. tuberculosis, M. leprae, and M. ulcerans

Mode of Action (MoA): Inhibits the mycobacterial cytochrome bc1 complex in the cellular respiration pathway.

Description: A novel class of small-molecule antibiotics shown to inhibit new targets within the M. tuberculosis mycolic acid biosynthesis pathway.

Mode of Action (MoA): Covalently inhibits the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in mycolic acid biosynthesis via a novel mode of inhibition.

Description: A novel class of small-molecule antibiotics shown to inhibit new targets within the M. tuberculosis mycolic acid biosynthesis pathway.

Mode of Action (MoA): Covalently inhibits the acyl transferase domain of Mtb Pks13, a polyketide synthase involved in mycolic acid biosynthesis via a novel mode of inhibition.

Description: A novel class of small-molecule antibiotics that targets several Mtb biosynthesis pathways.

Mode of Action (MoA): Inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and is involved in mycolic acid biosynthesis.

Description: A novel class of small-molecule antibiotics that targets several Mtb biosynthesis pathways.

Mode of Action (MoA): Inhibits FadD32, a key enzyme at the interface between the fatty acid synthase and polyketide synthase biosynthetic pathways and is involved in mycolic acid biosynthesis.

Description: H2L medChem for novel menaquinone biosynthesis inhibitors.

Mode of Action (MoA): Inhibits menG, a product of which catalyses methylation of demethylmenaquinone.

Description: Novel long-acting injectable formulation of bedaquiline for Tb preventive therapy.

Mode of Action (MoA): ATPase.

Description: Novel para-Aminosalicylic acid (PAS) analogues.

Mode of Action(MoA): Dihydrofolate reductase (DHFR).

Description: Exploring known host-directed therapies for TB treatment.

Mode of Action (MoA): Various.

Description: Target exploration of Mycobacterium transcription regulator (Mtr) complex. 

Mode of Action (MoA): Mycobacterium transcription regulator (Mtr).